Vericel Corp.
- VCEL ยท Nasdaq
- Biological Products, (No Diagnostic Substances)
- Burlington, MA
- 398 employees
- CIK 0000887359
Updated from SEC filings through
Top things to know
Executives
-
Dominick Colangelo President and CEO 4, 2026-02-26 -
Joseph Anthony Mara Jr Chief Financial Officer 4, 2026-06-30 - Joseph Mara Chief Financial Officer 10-K, 2026-02-26
- Michael Halpin Chief Operating Officer 4, 2026-08-05
-
Sean C. Flynn Chief Legal Officer 4, 2026-06-30 - Jonathan Mark Hopper Chief Medical Officer 4, 2026-06-30
What leadership is saying
“The Company delivered outstanding financial and business results in the third quarter as we continue to generate top-tier revenue and profit growth as well as significant free cash flow, while also returning capital to shareholders”
Earnings press release (8-K Ex. 99.1), filed November 5, 2026
Vericel Corp is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Burlington, MA. It trades as VCEL on Nasdaq. Revenue was $276M in the fiscal year ending December 31, 2025, +16.5% from the year before. It reported about 398 employees. Dominick Colangelo is President and CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $276M 10-K, 2026-02-26 | $237M 10-K, 2026-02-26 | $198M 10-K, 2026-02-26 | $164M 10-K, 2025-02-27 | $156M 10-K, 2024-02-29 |
| Operating income | $11.0M 10-K, 2026-02-26 | $4.5M 10-K, 2026-02-26 | -$6.5M 10-K, 2026-02-26 | -$17.1M 10-K, 2025-02-27 | -$7.9M 10-K, 2024-02-29 |
| SG&A | $167M 10-K, 2026-02-26 | $143M 10-K, 2026-02-26 | $121M 10-K, 2026-02-26 | $107M 10-K, 2025-02-27 | $97.6M 10-K, 2024-02-29 |
| Net income | $16.5M 10-K, 2026-02-26 | $10.4M 10-K, 2026-02-26 | -$3.2M 10-K, 2026-02-26 | -$16.7M 10-K, 2025-02-27 | -$7.5M 10-K, 2024-02-29 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Dominick Colangelo | President and CEO | 4, 2026-02-26 |
| Joseph Anthony Mara Jr Chief Financial Officer at Vericel Corporation | Chief Financial Officer | 4, 2026-06-30 |
| Joe Mara | Board member (per proxy) bio: Chief Financial Officer | DEF 14A, 2026-03-19 |
| Joseph Mara | Chief Financial Officer | 10-K, 2026-02-26 |
| Michael Halpin Chief Operating Officer at Vericel Corporation | Chief Operating Officer | 4, 2026-08-05 |
| Sean C. Flynn | Chief Legal Officer | 4, 2026-06-30 |
| Jonathan Mark Hopper | Chief Medical Officer | 4, 2026-06-30 |
| Sean Flynn | Chief Legal Officer | 10-K, 2026-02-26 |
| Karen Mahoney Chief Human Resources Officer | Chief Human Resources Officer | 4, 2025-12-12 |
| Jonathan Siegal | Principal Accounting Officer | 4, 2026-07-31 |
| Heidi Hagen | member of the Vericel Corporation Board of Directors | 10-K, 2026-02-26 |
What Vericel Corp does
Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets. We have a highly differentiated portfolio of cell therapy and specialty biologic products that combines innovations in biology with medical technologies. We were among the first companies to achieve commercial success in the complex field of cell therapies with treatments that use tissue engineering to regenerate skin and healthy knee cartilage.S.S.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 51.0 million (as of October 29, 2026) | 10-Q, November 5, 2026 |
|---|---|---|
| Public float | $2.1B (as of June 30, 2025) | 10-K, February 26, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 5, 2026 |
| Latest proxy statement | Meeting April 29, 2026 (filed March 19, 2026) | DEF 14A, March 19, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Boston, Massachusetts) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 6, 2026 | Joseph Anthony Mara Jr Chief Financial Officer | Sale | 50,000 | $2.7M | Form 4, November 9, 2026 |
| November 5, 2026 | Sean C. Flynn Chief Legal Officer | Sale | 15,000 | $779K | Form 4, November 6, 2026 |
| November 5, 2026 | Jonathan Siegal Principal Accounting Officer | Sale | 1,500 | $79K | Form 4, November 6, 2026 |
| November 5, 2026 | Robert L. Zerbe Md Director | Sale | 5,500 | $270K | Form 4, November 6, 2026 |
| August 12, 2026 | Kevin F. Mclaughlin Director | Sale | 7,000 | $312K | Form 4, August 14, 2026 |
| August 3, 2026 | Michael Halpin Chief Operating Officer | Sale | 10,000 | $468K | Form 4, August 5, 2026 |
| July 30, 2026 | Jonathan Siegal Principal Accounting Officer | Sale | 4,500 | $220K | Form 4, July 31, 2026 |
| June 26, 2026 | Jonathan Siegal Principal Accounting Officer | Sale | 2,732 | $123K | Form 4, June 30, 2026 |
Recent 8-K events
- 8-K filed 2026-11-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-30
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-18
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- 8-K filed 2026-05-07
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-01
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-02-26
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-13
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-11-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-07-31
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-05-08
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Vericel Corp
- What does Vericel Corp do?
- In its own words, from Item 1 of its 10-K: "Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets. We have a highly differentiated portfolio of cell therapy and specialty biologic products that combines innovations in biology with medical technologies. We were among the first companies to achieve commercial success in the complex field of cell therapies with treatments that use tissue engineering to regenerate skin and healthy knee cartilage.S.S."
- What is Vericel Corp's revenue?
- $276M for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is Vericel Corp profitable?
- Vericel Corp reported net income of $16.5M for the fiscal year ending December 31, 2025.
- How many employees does Vericel Corp have?
- About 398 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Vericel Corp?
- Dominick Colangelo, President and CEO, as named in a 4 filed February 26, 2026.
- Who is the CFO of Vericel Corp?
- Joseph Anthony Mara Jr, Chief Financial Officer, as named in a 4 filed June 30, 2026.
- Where is Vericel Corp headquartered?
- Burlington, MA.
- What is Vericel Corp's stock ticker?
- VCEL on Nasdaq.
- What industry is Vericel Corp in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Vericel Corp's website?
- vcel.com.
- When does Vericel Corp report earnings next?
- January 8, 2027. Source: estimate_8k_pattern.
- Is Vericel Corp a public company?
- Yes. Vericel Corp files with the SEC under CIK 0000887359 and trades as VCEL.
- Who audits Vericel Corp?
- PricewaterhouseCoopers LLP, Boston, Massachusetts, as named in its latest annual report (10-K).
- How many shares of Vericel Corp are outstanding?
- 51.0 million shares as of October 29, 2026, from its 10-Q filed November 5, 2026.
- What is Vericel Corp's public float?
- $2.1B as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- How many business segments does Vericel Corp report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 5, 2026.
- When is Vericel Corp's annual shareholder meeting?
- April 29, 2026, per its proxy statement (DEF 14A) filed March 19, 2026.
- Have Vericel Corp insiders traded stock recently?
- Since August 6, 2025, officers and directors reported 31 open-market sales worth about $12.3M and 0 purchases on Forms 4 and 5. The most recent: Joseph Anthony Mara Jr (Chief Financial Officer) sold 50,000 shares on November 6, 2026.